DDInter458 DDInter1702
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Sorafenib
Cyclosporine {u} (Compound) upregulates {v} (Gene) CDK7
CDK7 {u} (Gene) is bound by {v} (Compound) Sorafenib
Cyclosporine {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Sorafenib
Cyclosporine {u} (Compound) downregulates {v} (Gene) MCM3
MCM3 {u} (Gene) is downregulated by {v} (Compound) Sorafenib
Cyclosporine {u} (Compound) upregulates {v} (Gene) HMGCS1
HMGCS1 {u} (Gene) is downregulated by {v} (Compound) Sorafenib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Hepatobiliary disease {u} (Side Effect) is caused by {v} (Compound) Sorafenib
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Vismodegib
Vismodegib {u} (Compound) resembles {v} (Compound) Sorafenib
Cyclosporine {u} (Compound) upregulates {v} (Gene) CDK7
CDK7 {u} (Gene) is regulated by {v} (Gene) BRAF
BRAF {u} (Gene) is bound by {v} (Compound) Sorafenib
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) regulates {v} (Gene) CDK7
CDK7 {u} (Gene) is bound by {v} (Compound) Sorafenib
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Dapagliflozin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sorafenib
Cyclosporine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sorafenib (Compound)
Cyclosporine (Compound) upregulates CDK7 (Gene) and CDK7 (Gene) is bound by Sorafenib (Compound)
Cyclosporine (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Sorafenib (Compound)
Cyclosporine (Compound) downregulates MCM3 (Gene) and MCM3 (Gene) is downregulated by Sorafenib (Compound)
Cyclosporine (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene) is downregulated by Sorafenib (Compound)
Cyclosporine (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Sorafenib (Compound)
Cyclosporine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Vismodegib (Compound) and Vismodegib (Compound) resembles Sorafenib (Compound)
Cyclosporine (Compound) upregulates CDK7 (Gene) and CDK7 (Gene) is regulated by BRAF (Gene) and BRAF (Gene) is bound by Sorafenib (Compound)
Cyclosporine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) regulates CDK7 (Gene) and CDK7 (Gene) is bound by Sorafenib (Compound)
Cyclosporine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dapagliflozin (Compound) and Dapagliflozin may cause a minor interaction that can limit clinical effects when taken with Sorafenib